Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb;9(2):122-123.
doi: 10.1016/S2213-2600(20)30523-3. Epub 2020 Nov 12.

Nebulised interferon beta-1a for patients with COVID-19

Nathan Peiffer-Smadja  1 , Yazdan Yazdanpanah  2
Affiliations
Comment

Nebulised interferon beta-1a for patients with COVID-19

Nathan Peiffer-Smadja et al. Lancet Respir Med. 2021 Feb.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30511-7. published online Nov 12. - DOI - PMC - PubMed
    1. Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178 - PMC - PubMed
    1. Arabi YM, Asiri AY, Assiri AM, et al. Interferon beta-1b and lopinavir–ritonavir for Middle East Respiratory Syndrome. N Engl J Med. 2020;383:1645–1656. - PubMed
    1. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724. - PMC - PubMed
    1. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370 - PMC - PubMed